Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – What’s Next?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw strong trading volume on Tuesday . 874,583 shares changed hands during mid-day trading, an increase of 351% from the previous session’s volume of 193,766 shares.The stock last traded at $26.98 and had previously closed at $26.52.

Wall Street Analyst Weigh In

CHGCY has been the topic of several analyst reports. Smbc Nikko Sec. raised Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, February 25th. UBS Group upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock has an average rating of “Strong Buy”.

Chugai Pharmaceutical Stock Performance

The company has a market capitalization of $96.33 billion, a P/E ratio of 33.64 and a beta of 0.60. The firm’s fifty day moving average is $29.22 and its 200 day moving average is $26.48.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Thursday, January 29th. The company reported $0.25 earnings per share (EPS) for the quarter. The business had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%. On average, analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.